ATLANTA, GA — March 20, 2002 — Preliminary clinical study results announced today demonstrate that the investigational drug Vanlev (omapatrilat), a novel vasopeptidase inhibitor, was as effective as the ACE-inhibitor enalapril, in the treatment of heart failure. The results of the OVERTURE (Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events) study were presented today during a Late Breaking Clinical Trial session at the 51st Annual Scientific Session of the American College of Cardiology.
"Heart failure is a debilitating, often fatal disease that affects millions of people," said Milton Packer, M.D., Chairman of the OVERTURE Study Executive Committee and Professor of Medicine at the Columbia College of Physicians and Surgeons in New York. "The OVERTURE study shows that Vanlev delivers a similar magnitude of benefit as the current gold standard enalapril, in the treatment of heart failure."
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!